Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requirs specific intervention.
Landiolol is not intended for use in chronic settings.
Active ingredient: Landiolol | Pharmaceutical form: Concentrate & powder for the Injection solution | Strength: 20 mg/2 ml (concentrate), 300 mg (powder)
Marketing authorisation holder: Amomed Pharma GmbH